Basis: Current FMP quote-based enterprise value / four-quarter operating income plus matched D&A. Source: stored company filings and market data; unavailable inputs remain N/A.
The EV/EBITDA ratio is N/A as of 2026-10-06T15:47:31.368Z.
Calculation as of: 2026-10-06T15:47:31.368Z.
Quote observation: 2026-10-06T15:44:29.000Z. Amounts in USD. The price header may show a later quote.
FMP input reference: 11bda5a52c13142378ae00f1a27abc282066b453892c652a9842cb594787c7ab
Historical values estimate market capitalization from statement-period weighted shares. Comparisons with the current quote-based value are approximate. Only filing versions delivered by FMP are available for the historical calculation.
EV/EBITDA RATIO
N/A
MaxCyte, Inc.
Market Cap
$114.08M
EV/EBITDA Ratio
N/A
| NAME | MARKET CAP | EV/EBITDA RATIO |
|---|---|---|
| MaxCyte, Inc. (MXCT) | $114.08M | N/A |
| Lucid Diagnostics Inc. (LUCD)vs › | $115.36M | N/A |
| Coya Therapeutics, Inc. (COYA)vs › | $116.35M | N/A |
| Genelux Corporation (GNLX)vs › | $116.59M | N/A |
| Foghorn Therapeutics Inc. (FHTX)vs › | $116.34M | N/A |
| BGM Group Ltd. (BGM)vs › | $111.14M | N/A |
| Insight Molecular Diagnostics Inc. (IMDX)vs › | $116.89M | N/A |
| Aardvark Therapeutics, Inc. Common Stock (AARD)vs › | $110.95M | N/A |
| Immunic, Inc. (IMUX)vs › | $110.27M | N/A |
| Caribou Biosciences, Inc. (CRBU)vs › | $117.53M | N/A |
EV/EBITDA = Enterprise Value / EBITDA (TTM)
Enterprise value to EBITDA is a capital-structure-neutral valuation multiple, useful for comparing companies with different debt levels and tax rates.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
